2-(4-Acetamido-2,6-dichlorphenylimino)-imidazolidin | 73218-85-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Acetamido-2,6-dichlorphenylimino)-imidazolidin
• 英文别名: N-[3,5-dichloro-4-(4,5-dihydro-1H-imidazol-2-ylamino)-phenyl]-acetamide；N-[3,5-dichloro-4-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]acetamide
• CAS: 73218-85-6
• 化学式: C₁₁H₁₂Cl₂N₄O
• 分子量: 287.148
• InChiKey: UYOCYPVWZNEXKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  65.5
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-Acetamido-2,6-dichlorphenylimino)-imidazolidin 、 硼烷 、 二甲基硫 以53%的产率得到
  参考文献：
  名称：

  ROUOT B.; LECLERC G., BULL. SOC. CHIM. FRANCE, 1979, PART 2, NO 9-10, 520-528

  摘要：

  DOI：
• 作为产物：
  描述：

  阿可乐定 、 乙酰氯 以95%的产率得到
  参考文献：
  名称：

  ROUOT B.; LECLERC G., BULL. SOC. CHIM. FRANCE, 1979, PART 2, NO 9-10, 520-528

  摘要：

  DOI：

文献信息

• Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
  申请人：Sun Pharma Advanced Research Company Limited

  公开号：US10172852B2

  公开（公告）日：2019-01-08

  The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.

  本发明涉及一种提高药物的生物利用度和/或延长药物眼部作用的方法，该方法包括向眼部灌注一种水悬浮液，该水悬浮液包含载药纳米树脂颗粒的可逆团簇，所述团簇的 D50 值至少为 2 微米，所述载药纳米树脂颗粒的粒度分布特征在于 D90 值为 70 纳米至 900 纳米。本发明进一步涉及一种水性悬浮液，该悬浮液包含载药纳米树脂颗粒的可逆簇，所述簇的 D50 值至少为 2 微米，所述载药纳米树脂颗粒的粒度分布特征在于 D90 值为 70 纳米至 900 纳米。
• Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
  申请人：ONXEO

  公开号：US10675271B2

  公开（公告）日：2020-06-09

  The present invention pertains to specific clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. It also pertains to the use of this clonidine and/or clonidine derivative for the manufacture of a pharmaceutical composition intended to prevent and/or alleviate the adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. This invention is further directed to a kit comprising: (a) a clonidine and/or clonidine derivative, and (b) at least one alkylating chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.

  本发明涉及用于预防和/或治疗烷化剂化疗不良副作用（粘膜炎症引起的副作用除外）的特定氯尼定和/或氯尼定衍生物。本发明还涉及使用这种氯尼地定和/或氯尼地定衍生物制造药物组合物，以预防和/或减轻烷化剂化疗的不良副作用（粘膜炎症引起的副作用除外）。本发明还涉及一种试剂盒，包括：(a)一种氯尼地定和/或氯尼地定衍生物，和(b)至少一种烷化剂化疗药，作为一种联合制剂，可同时、单独或依次用于治疗癌症。
• Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
  申请人：MONOPAR THERAPEUTICS INC.

  公开号：US11090290B2

  公开（公告）日：2021-08-17

  The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.

  本发明涉及一种药物组合物，该组合物由药学上可接受的载体和作为唯一活性成分的氯硝柳胺和/或氯硝柳胺衍生物组成，用于通过经黏膜给药预防放疗导致的皮肤损伤。
• Topical compostions for lowering intraocular pressure
  申请人：ALCON LABORATORIES, INC.

  公开号：EP0081924B1

  公开（公告）日：1986-02-19
• Sustained-release compositions containing cation exchange resins and polycarboxylic polymers
  申请人：ALCON LABORATORIES, INC.

  公开号：EP0429732B1

  公开（公告）日：1994-03-16